Drug Profile
Leucine/sildenafil - NuSirt Biopharma
Alternative Names: Leu Sil; NS-0300; Sildenafil/leucine; Sildenafil/leucine - NuSirt BiopharmaLatest Information Update: 17 Mar 2021
Price :
$50
*
At a glance
- Originator NuSirt Biopharma
- Class Branched-chain amino acids; Erectile dysfunction therapies; Essential amino acids; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
- Mechanism of Action Gluconeogenesis inhibitors; SIRT1 protein stimulants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 17 Mar 2021 No development reported - Phase-II for Obesity in USA (PO)
- 17 Aug 2018 NuSirt Biopharma completes a phase II trial in Obesity in USA (PO) (NCT03364335)
- 08 Jan 2018 Phase-II clinical trials in Obesity in USA (PO) (NCT03364335)